Ovarian Cancer: Related News

On Our Blog

Pictured: Yukio Sonoda
Meet Gynecologic Cancer Surgeon Yukio Sonoda

Dr. Sonoda, who performs minimally invasive procedures when possible, discusses how patients at Memorial Sloan-Kettering have the benefit of an entire team of physicians having input into their care.

March 27, 2013
Pictured: Dennis Chi & Richard Barakat
Women with Ovarian Cancer Benefit from Treatment at High-Volume Centers

Gynecology Service Chief Richard Barakat comments on a recent study indicating that women treated by more-experienced physicians receive the most-appropriate care for this aggressive form of cancer.

March 12, 2013
Pictured: Dennis Chi
Meet Gynecologic Cancer Surgeon Dennis Chi

Dr. Chi, Deputy Chief of the Gynecology Service, talks about the way Memorial Sloan-Kettering’s research and state-of-the-art care help women with ovarian, cervical, and uterine cancers.

February 13, 2013
Pictured: Richard Barakat
Meet Gynecologic Surgeon Richard Barakat

Dr. Barakat explains the latest surgical techniques for improving outcomes and quality of life in women with cervical, ovarian, and other gynecologic cancers.

December 28, 2012
Pictured: Carol Brown
Meet Gynecologic Cancer Surgeon Carol Brown

Gynecologic cancer surgeon Dr. Brown discusses how doctors and nurses collaborate to care for patients, from diagnosis through lifelong follow-up.

November 28, 2012
Pictured: Nadeem Abu-Rustum
Meet Gynecologic Surgeon Nadeem Abu-Rustum

Dr. Abu-Rustum, Director of Minimally Invasive Surgery for the Gynecology Service, discusses how the gynecologic cancer care team treats each woman with an individualized approach.

October 22, 2012
Pictured: Richard Barakat
Gynecologic Surgeon Richard Barakat to Be Appointed President of Two Leading Medical Societies

Dr. Barakat will serve as president of two prestigious societies for gynecologic cancer, allowing him to influence how women with these cancers are cared for both in the United States and around the world.

October 1, 2012
Pictured: Jane McGrath
Jane’s Story about Ovarian Cancer

When 45-year-old Jane learned she had a tumor in her ovary, she came to Memorial Sloan-Kettering for surgery and chemotherapy.

August 7, 2012
Pictured: Memorial Sloan-Kettering logo
Memorial Sloan-Kettering Made Major Contributions to Cancer Advances in 2011

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan-Kettering investigators.

February 6, 2012
Pictured: Paul Sabbatini
Oncologist Paul Sabbatini Talks About New Strategies to Treat Ovarian Cancer

Medical oncologist Paul Sabbatini, a specialist in treating gynecologic cancers, leads a clinical research program seeking to improve treatments for ovarian cancer by harnessing the power of the immune system.

October 31, 2011
Pictured: Douglas Levine
Genomic Analysis Provides Clues about Most Common Form of Ovarian Cancer

In a large-scale genomic analysis of the most common and aggressive type of ovarian cancer, researchers from Memorial Sloan-Kettering and other centers identified genetic mutations and pathways that set the disease apart from other types of ovarian cancer and other solid tumors.

October 11, 2011
Pictured: Jedd Wolchok & Paul Chapman
Memorial Sloan-Kettering Physician-Scientists Present Significant Clinical Cancer Research Advances at ASCO Annual Meeting

In an extraordinary demonstration of excellence, five Memorial Sloan-Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.

July 1, 2011

Related Media Coverage

First Comprehensive Analysis Of Gene Mutations In Ovarian Cancer Brings Patients One Step Closer To Personalized Medicine

According to a large-scale genomic analysis of the most common and aggressive type of ovarian cancer, researchers from Memorial Sloan- Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) project identified genetic mutations and pathways that distinctly set the disease apart not only from other types of ovarian cancer, but from other solid tumors as well.

June 29, 2011
Carol Aghajanian
New Drug Combination Slows Tumor Growth For Recurrent Ovarian Cancer

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan-Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

June 4, 2011

On Cancer

News and Insights from
Memorial Sloan-Kettering
Read Our Blog »

Center News

Pictured: Center News, April 2013
Read Our Magazine »

Subscribe to Our E-newsletter

Get the latest information about cancer care.